BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 32649877)

  • 1. Integrative Proteomic Characterization of Human Lung Adenocarcinoma.
    Xu JY; Zhang C; Wang X; Zhai L; Ma Y; Mao Y; Qian K; Sun C; Liu Z; Jiang S; Wang M; Feng L; Zhao L; Liu P; Wang B; Zhao X; Xie H; Yang X; Zhao L; Chang Y; Jia J; Wang X; Zhang Y; Wang Y; Yang Y; Wu Z; Yang L; Liu B; Zhao T; Ren S; Sun A; Zhao Y; Ying W; Wang F; Wang G; Zhang Y; Cheng S; Qin J; Qian X; Wang Y; Li J; He F; Xiao T; Tan M
    Cell; 2020 Jul; 182(1):245-261.e17. PubMed ID: 32649877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
    Bao X; Shi R; Zhao T; Wang Y
    Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the alternation landscape of mitochondrial metabolism-related genes in lung adenocarcinoma and their latent mechanisms.
    Jin X; Liu D; Kong D; Zhou X; Zheng L; Xu C
    Aging (Albany NY); 2023 Jun; 15(12):5482-5496. PubMed ID: 37335087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts.
    Zhou J; Liu B; Li Z; Li Y; Chen X; Ma Y; Yan S; Yang X; Zhong L; Wu N
    Mol Cell Proteomics; 2021; 20():100015. PubMed ID: 33508502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of
    Hou Y; Tan S; Wang G
    Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene Expression Classification of Lung Adenocarcinoma into Molecular Subtypes.
    Hu F; Zhou Y; Wang Q; Yang Z; Shi Y; Chi Q
    IEEE/ACM Trans Comput Biol Bioinform; 2020; 17(4):1187-1197. PubMed ID: 30892233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Resolution Profiling of Lung Adenocarcinoma Identifies Expression Subtypes with Specific Biomarkers and Clinically Relevant Vulnerabilities.
    Roh W; Geffen Y; Cha H; Miller M; Anand S; Kim J; Heiman DI; Gainor JF; Laird PW; Cherniack AD; Ock CY; Lee SH; Getz G;
    Cancer Res; 2022 Nov; 82(21):3917-3931. PubMed ID: 36040373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioinformatic analysis revealing mitotic spindle assembly regulated NDC80 and MAD2L1 as prognostic biomarkers in non-small cell lung cancer development.
    Wei R; Wang Z; Zhang Y; Wang B; Shen N; E L; Li X; Shang L; Shang Y; Yan W; Zhang X; Ma W; Wang C
    BMC Med Genomics; 2020 Aug; 13(1):112. PubMed ID: 32795325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
    Chen C; Tang Y; Qu WD; Han X; Zuo JB; Cai QY; Xu G; Song YX; Ke XX
    BMC Cancer; 2021 May; 21(1):619. PubMed ID: 34039308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CASC5 is a potential tumour driving gene in lung adenocarcinoma.
    Cui Y; Zhang C; Ma S; Guo W; Cao W; Guan F
    Cell Biochem Funct; 2020 Aug; 38(6):733-742. PubMed ID: 32283571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIMM17A overexpression in lung adenocarcinoma and its association with prognosis.
    Miao L; Wu D; Zhao H; Xie A
    Sci Rep; 2024 Apr; 14(1):8840. PubMed ID: 38632467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prognostic 14-Gene Expression Signature for Lung Adenocarcinoma: A Study Based on TCGA Data Mining.
    Liu J; Hou S; Wang J; Chai Z; Hong X; Zhao T; Sun Z; Bai L; Gao H; Gao J; Chen G
    Oxid Med Cell Longev; 2020; 2020():8847226. PubMed ID: 33414898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic profiling of tumor microenvironment and prognosis risk prediction in stage I lung adenocarcinoma.
    Lu YF; Chang YH; Chen YJ; Hsieh MS; Lin MW; Hsu HH; Han CL; Chen YJ; Yu SL; Chen JS; Chen HY
    Lung Cancer; 2024 May; 191():107791. PubMed ID: 38621342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
    Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
    Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.
    Gillette MA; Satpathy S; Cao S; Dhanasekaran SM; Vasaikar SV; Krug K; Petralia F; Li Y; Liang WW; Reva B; Krek A; Ji J; Song X; Liu W; Hong R; Yao L; Blumenberg L; Savage SR; Wendl MC; Wen B; Li K; Tang LC; MacMullan MA; Avanessian SC; Kane MH; Newton CJ; Cornwell M; Kothadia RB; Ma W; Yoo S; Mannan R; Vats P; Kumar-Sinha C; Kawaler EA; Omelchenko T; Colaprico A; Geffen Y; Maruvka YE; da Veiga Leprevost F; Wiznerowicz M; Gümüş ZH; Veluswamy RR; Hostetter G; Heiman DI; Wyczalkowski MA; Hiltke T; Mesri M; Kinsinger CR; Boja ES; Omenn GS; Chinnaiyan AM; Rodriguez H; Li QK; Jewell SD; Thiagarajan M; Getz G; Zhang B; Fenyö D; Ruggles KV; Cieslik MP; Robles AI; Clauser KR; Govindan R; Wang P; Nesvizhskii AI; Ding L; Mani DR; Carr SA;
    Cell; 2020 Jul; 182(1):200-225.e35. PubMed ID: 32649874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.